Development status: Inactive

Gram-positive activity

Mechanism of Action/Target pathogen: Inhibits dihydrofolic acid reductase and thus, the synthesis of purine. Active against Gram-positive bacteria including trimethoprim-resistant strains.

Reason dropped: Rejected by the FDA due to failure to show non-inferiority and due to safety concerns

Additional information: Synthetic compound. Trimethoprim derivative